Literature DB >> 3711752

Diagnostic implications of figure-of-eight and clockwise QRS loop rotation on the horizontal vectorcardiogram in chronic aortic valve disease.

S H Recke.   

Abstract

In chronic aortic valve disease the left ventricular (LV) volumes, mass and ejection fraction (EF), as well as selected Frank ECG measurements of patients with a normal counterclockwise rotation (Type A) of the horizontal QRS vector loop are compared with those of patients showing an abnormal figure-of-eight or clockwise configuration (Type B) to investigate whether the different QRS patterns reflect ventriculographic alterations or depends on a conduction delay. In aortic stenosis (AS,n = 21) and combined AS and aortic insufficiency (AS + AI,n = 23) the Type B vectorcardiograms (VCGs) correlate with significantly increased LV end-diastolic volumes (p. .01, .01, respectively) and depressed EF (p .07, .009, respectively). In pure AI (n = 39) LV volumes, mass and EF do not differ between the Type A and Type B patterns. As compared to Type B VCGs of AS (n = 6), the LV end-diastolic volume index is clearly higher in Type A VCGs of pure AI (n = 21)(p .028). The only ECG change which is significant at the p .01 level in each group is the increase of the R peak time in lead X in the Type B VCGs. This can be related to greater volume and mass only in AS and AS+ AI, but is not substantiated by equivalent ventriculographic alterations in pure AI. The findings indicate that Type B VCGs are very likely caused by a left ventricular conduction delay since they cannot be strictly correlated with increases in LV volume and mass alone.

Entities:  

Mesh:

Year:  1986        PMID: 3711752     DOI: 10.1016/s0022-0736(86)80019-x

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  1 in total

1.  Left ventricular function-conduction impairment as reflected by the ECG in chronic aortic regurgitation.

Authors:  Siegfried H Recke
Journal:  Wien Klin Wochenschr       Date:  2011-07-05       Impact factor: 1.704

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.